CREXAVIBART
UNII ME6UG23L4A

Substance Identification & Data

This profile provides standardized clinical and technical data for Crexavibart, uniquely identified by the FDA Unique Ingredient Identifier (UNII) ME6UG23L4A.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2599039-61-7 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

ME6UG23L4A

CAS Registry Number

2599039-61-7

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

CREXAVIBART

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C188601

National Cancer Institute reference terminology for clinical and research data.

INN ID

12362

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

JK-239

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Crexavibart. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

CREXAVIBART

Common Names & Synonyms

CREXAVIBART [INN]

CREXAVIBART [USAN]

CREXAVIBART [WHO-DD]

IMMUNOGLOBULIN G1 (442-LEUCINE,448-SERINE,DE-461-LYSINE), ANTI-(SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SPIKE GLYCOPROTEIN RECEPTOR-BINDING DOMAIN) (HUMAN MONOCLONAL C144 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL C144 .LAMBDA.-CHAIN, DIMER

IMMUNOGLOBULIN G1-LAMBDA2, ANTI-(SEVERE ACUTE RESPIRATORY SYNDROME (HUMAN) CORONAVIRUS 2 (SARS-COV-2) SPIKE (S) GLYCOPROTEIN, RECEPTOR BINDING DOMAIN (RBD)), HOMO SAPIENS MONOCLONAL ANTIBOD